期刊
PLATELETS
卷 32, 期 1, 页码 29-42出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/09537104.2020.1849600
关键词
GPVI; CLEC-2; tyrosine kinase; antiplatelet; Btk
资金
- BHF Chair [CH03/003]
Antiplatelet medications are crucial in treating diseases involving arterial thrombosis, but may cause bleeding and recurrence of thrombotic events. Targeting platelet GPVI and CLEC-2 receptors could offer novel treatment strategies with enhanced antithrombotic efficacy and minimal disruption to hemostasis. Further research into these receptors and their inhibition strategies is needed for effective prevention of platelet recruitment and activation in thrombotic diseases.
Antiplatelet medications comprise the cornerstone of treatment for diseases that involve arterial thrombosis, including acute coronary syndromes (ACS), stroke and peripheral arterial disease. However, antiplatelet medications may cause bleeding and, furthermore, thrombotic events may still recur despite treatment. The interaction of collagen with GPVI receptors on the surface of platelets has been identified as one of the major players in the pathophysiology of arterial thrombosis that occurs following atherosclerotic plaque rupture. Promisingly, GPVI deficiency in humans appears to have a minimal impact on bleeding. These findings together suggest that targeting platelet GPVI may provide a novel treatment strategy that provides additional antithrombotic efficacy with minimal disruption of normal hemostasis compared to conventional antiplatelet medications. CLEC-2 is gaining interest as a therapeutic target for a variety of thrombo-inflammatory disorders including deep vein thrombosis (DVT) with treatment also predicted to cause minimal disruption to hemostasis. GPVI and CLEC-2 signal through Src, Syk and Tec family tyrosine kinases, providing additional strategies for inhibiting both receptors. In this review, we summarize the evidence regarding GPVI and CLEC-2 and strategies for inhibiting these receptors to inhibit platelet recruitment and activation in thrombotic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据